THEMIS MEDICARE share price has zoomed 7% and is presently trading at Rs 255.0.
Meanwhile, the BSE HEALTHCARE index is at 43,878.0 (up 1.2%).
Among the top gainers in the BSE HEALTHCARE index today are AJANTA PHARMA (up 3.5%) and SUVEN PHARMACEUTICALS (up 3.1%).
ALEMBIC PHARMA (down 1.8%) and Jubilant Pharmova (down 1.6%) are among the top losers today.
Over the last one year, THEMIS MEDICARE has moved up from Rs 159.7 to Rs 255.0, registering a gain of Rs 95.3 (up 59.7%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,357.7 to 43,878.0, registering a gain of 54.7% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were SUVEN PHARMACEUTICALS (up 140.6%), Jubilant Pharmova (up 123.1%) and Glenmark Pharma (up 118.8%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 81,691.1 (up 0.2%).
The top gainers among the BSE Sensex today are Power Grid Corp. (up 1.4%) and Bharti Airtel (up 1.3%). The most traded stocks in the BSE Sensex are Tata Steel and SBI.
In the meantime, NSE Nifty is at 25,007.0 (up 0.3%). Power Grid Corp. and Divis Laboratories are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,880.5 to 81,691.1, registering a gain of 15,810.6 points (up 24.0%).
THEMIS MEDICARE net profit grew 49.0% YoY to Rs 187 million for the quarter ended June 2024, compared to a profit of Rs 126 million a year ago. Net sales rose 27.3% to Rs 1,230 million during the period as against Rs 966 million in April-June 2023.
For the year ended March 2024, THEMIS MEDICARE reported 23.5% decrease in net profit to Rs 435 million compared to net profit of Rs 569 million during FY23. Revenue of the company grew 7.7% to Rs 3,818 million during FY24.
The current Price to earnings ratio of THEMIS MEDICARE, based on rolling 12 month earnings, stands at 76.0.
Equitymaster requests your view! Post a comment on "THEMIS MEDICARE Gains 7%; BSE HEALTHCARE Index Up 1.2%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!